Merit Medical Q4 revenue rises 11% to $393.9 million; 2026 guidance set
Merit Medical reported fourth-quarter 2025 revenue of $393.9 million, up 11%, and non-GAAP EPS of $1.04, up 12%. For fiscal 2026 it guided to total revenue of $1.610 billion to $1.630 billion and non-GAAP EPS of $4.01 to $4.15, implying growth of 6% to 8% and 5% to 8%, respectively.
Key points
- Q4 2025 GAAP EPS was $0.63, up from $0.46 a year earlier; non-GAAP EPS was $1.04 versus $0.93.
- Full-year 2025 revenue was $1.516 billion, up 12%, and non-GAAP EPS was $3.83, up 11%.
- 2026 guidance: revenue of $1.610 billion to $1.630 billion and non-GAAP EPS of $4.01 to $4.15, excluding possible effects of trade policies and unannounced acquisitions.
- Q4 2025 free cash flow was $74.0 million, up 13%.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 24, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.